Clinical trials: Blood Pressure, High
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan
Hypertension
Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension
To evaluate efficacy and tolerability of Micardis® / MicardisPlus® under usual daily-practice prescribing conditions with a special emphasis on controlling morning blood pressure
- Trial name
- NCT02242383
- Testing
- Telmisartan, Telmisartan in combination with hydrochlorothiazide
- Volunteers
- 13,248 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Hypertension
Evaluation of Sympathetic Activity Effects by the BackBeat Medical Cardiac Neuromodulation Therapy (CNT).
Measurement and recording of Muscle Sympathetic Neural Activity (MSNA) using microneurography, will be applied to subjects who have been already implanted with a Moderato IPG delivering the BackBeat CNT and/or pacing signals.
- Trial name
- NCT05462405
- Testing
- Experimental group
- Where
- Hungary
- Volunteers
- 15 people
- Sponsor
- BackBeat Medical Inc
Arterial Hypertension, Diabetes
Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium
Cicletanine, which has been approved and launched for hypertension in France and Germany, has promise beyond hypertension in critically-unmet needs such as diabetes.
- Conditions
- Arterial Hypertension, Diabetes, Hypokalemia, Hyponatremia
- Trial name
- CHAMP (NCT02709031)
- Testing
- Cicletanine + magnesium, Cicletanine
- Volunteers
- 24 people
- Sponsor
- Navitas Pharma
Hypertension
Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment
The purpose of this study is to evaluate the clinical efficacy of indapamide 1.5mg / losartan 50mg and indapamide 1.5mg / losartan 100mg on reduction of blood pressure.
- Trial name
- NCT01620788
- Testing
- Indapamide / Losartan, Hyzaar®
- Where
- Brazil
- Volunteers
- 636 people
- Sponsor
- EMS
Hypertension
The "Global Paradise System" Registry
The GPS Registry is a multi-centre, single-arm, non-interventional (observational) registry. In addition to collecting data from patients treated as per standard clinical practice, the Registry will also regularly collect…
- Trial name
- GPSRegistry (NCT05027685)
- Testing
- The Paradise Ultrasound Renal Denervation System
- Where
- 55 sites in Austria, Belgium and 7 more
- Volunteers
- 3,000 people
- Sponsor
- ReCor Medical, Inc.
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Glaucoma, Ocular Hypertension
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT02136940
- Testing
- AMA0076
- Where
- 9 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amakem, NV
Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the intraocular pressure (IOP)-lowering efficacy and safety of two combination products in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00333125
- Testing
- Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav), Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt), Timolol Vehicle
- Volunteers
- 319 people
- Sponsor
- Alcon Research
Hypertensive Disease
SMART-IC-Pilot Study
This small-scale, proof-of-concept pilot study aims to obtain preliminary evidence of msRDN procedural safety, feasibility, and short-term efficacy in patients with hypertension without medication therapy, to adequately plan an…
- Trial name
- SMART-IC-Pilot (NCT07336433)
- Testing
- The SymPioneer G2 Mapping/Selective Renal Denervation Device and SyMapCath Catheter II
- Where
- China
- Volunteers
- 15 people
- Sponsor
- SyMap Medical (Suzhou), Ltd.
Hypertension, Hypertension, Systolic
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure…
- Conditions
- Hypertension, Hypertension, Systolic, Hypertension, Essential
- Trial name
- BACKBEAT (NCT06059638)
- Testing
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Where
- 131 sites in United States, Australia and 13 more
- Volunteers
- 316 people
- Sponsor
- Orchestra BioMed, Inc
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pediatric Hypertension
A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
The purpose of this study is to evaluate the safety of administration of azilsartan in pediatric patients aged 6 to less than 16 years with hypertension.
- Trial name
- NCT02791438
- Testing
- Azilsartan
- Where
- 30 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Takeda
Essential Hypertension, Atherosclerotic Cardiovascular Disease
Olmesartan Medoxomil in Atherosclerosis
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.
- Trial name
- NCT00185185
- Testing
- Olmesartan medoxomil, Atenolol, Hydrochlorothiazide
- Where
- Germany
- Volunteers
- 165 people
- Sponsor
- Sankyo Pharma Gmbh
Hypertension
Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria
To evaluate the effects and safety of irbesartan on proteinuria in hypertensive patients with type Ⅱdiabetes mellitus.
- Trial name
- PRIME (NCT00561964)
- Testing
- Irbesartan
- Volunteers
- 241 people
- Sponsor
- Sanofi
Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
- Trial name
- NCT05397600
- Testing
- Bimatoprost Ophthalmic
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 684 people
- Sponsor
- Laboratoires Thea
Hypertension
Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension
Study to assess the safety of six month of open-label, treatment with the fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in a subset of patients with mild-to-moderate hypertension who completed the…
- Trial name
- NCT02177487
- Testing
- Telmisartan/hydrochlorothiazide
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Metabolic Syndrome X
Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities
The objective of the study is to compare PPAR activities (increase of adiponectin level) between MICARDIS and amlodipine after 6 weeks of treatment in hypertensive patients with metabolic syndrome.
- Trial name
- NCT00242814
- Testing
- Micardis, Amlodipine, Abdominal biopsy
- Where
- 31 sites in France
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015-A and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT07421401
- Testing
- BR1015-A, BR1015-3, BR1015-2
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.